Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?

Abstract

A review of incretin-based medications in T2D as recommended in recent international guidelines, with special consideration of glucose-lowering efficacy, cardiovascular benefit, body weight, hypoglycaemia risk and economic implications.

Citation
Davies MJ, Bianchi C, Del Prato S. Metabolism 2020;107:154242.